The Ras/MEK/ERK pathway has been the primary focus of targeted therapies in melanoma; it is aberrantly activated in almost 80% of human cutaneous melanomas (~50% BRAF V600 mutations and ~30% NRAS mutations). While targeted therapies have yielded success in BRAF V600 mutant melanoma patients, such therapies have been ineffective in NRAS mutant melanomas in part due to their cytostatic effects and primary resistance in this patient population. Here, we demonstrate that increased Rho/MRTF-pathway activation correlates with high intrinsic resistance to the MEK inhibitor, trametinib, in a panel of NRAS mutant melanoma cell lines. Combination of trametinib with the Rho/MRTF-pathway inhibitor, CCG-222740, synergistically reduced cell viability in NRAS mutant melanoma cell lines in vitro. Furthermore, the combination of CCG-222740 with trametinib induced apoptosis and reduced clonogenicity in SK-Mel-147 cells which have a high level of trametinib resistance. These findings suggest a role of the Rho/MRTF-pathway in intrinsic trametinib resistance in a subset of NRAS mutant melanoma cell lines and highlights the potential of concurrently targeting the Rho/MRTF-pathway and MEK in NRAS mutant melanomas.
INTRODUCTION
With expanding knowledge of the genomic landscape of melanoma, targeted therapies have been evolving over the last decade (1). Almost half of melanoma patients harbor BRAF V600 mutations, followed by the second most common oncogenic driver mutations occurring in the NRAS gene in approximately 30% of melanoma patients (2, 3) . A number of FDA approved targeted therapies have become standard of care in BRAF mutant melanoma patients. Inhibitors targeting mutant BRAF, such as vemurafenib and dabrafenib, were initially employed as monotherapies.
In recent years, BRAF/MEK inhibitor combinations including debrafenib/trametinib, vemurafenib/cometinib, and encorafenib/binimetinib have been approved by the FDA, leading to median progression-free survival (PFS) of up to 14.9 months in BRAF mutant melanoma patients (4) . Compared to melanoma patients with BRAF V600 mutations, patients with activating NRAS mutations are associated with more aggressive disease progression and poor prognosis (5) . To date, NRAS mutant melanoma patients have limited treatment options consisting of chemotherapeutics and immunotherapies, both of which are associated with high toxicity (6) (7) (8) (9) . Unfortunately, targeted therapies for NRAS mutant melanoma patients are sorely lacking.
N-Ras protein targeted small molecule inhibitors have been difficult to design and efforts to inhibit posttranslational modification of N-Ras via farnesyltransferase inhibitors have not yielded approved therapies yet (10) (11) (12) . Therefore, efforts to develop targeted therapies for NRAS mutant melanomas have focused on signaling components downstream of NRAS in the MAPK pathway, such as mitogen-activated protein kinase kinase (MEK). Only a subset of patients benefits from MEK inhibitors used as single agents, because they only produce cytostatic effects rather than cytotoxic effects, in NRAS mutant melanoma cells (13) . MEK inhibitors are also associated with primary and acquired resistance as well as frequent toxicity-related adverse events (14, 15) . However, MEK inhibitors could deliver promising therapies when combined with inhibitors of other signaling mechanisms (12, (15) (16) (17) . Currently, the MEK inhibitor FCN-159, which has 10-fold higher selectivity against activated MEK1/2 compared to trametinib, is being investigated as a single agent in a phase I clinical trial (NCT03932253). Additionally, clinical trials for the MEK inhibitor trametinib in combination with an ErbB3 antibody (NCT03580382) or a pan-RAF inhibitor, LXH254, (NCT02974725) are currently underway.
However, all of these studies are still in early-phase clinical trials. Furthermore, primary and acquired resistance to some of the combinations, such as the MEK inhibitor MEK162 with a CDK4/6 inhibitor (18, 19) , are emerging. Therefore, there is a continued need to understand the mechanism of resistance of NRAS mutant melanomas to MEK inhibitors and to develop new treatment strategies.
In cutaneous melanoma patients, increased expression of RhoC or MRTF-A mRNA has been linked to overall poor patient survival (20) . Myocardin-related transcription factor (MRTF) is a pair (MRTF-A and -B) of transcription cofactors downstream of Rho GTPases (21, 22) . Rho
GTPases regulate the actin cytoskeleton and have long been demonstrated to play a critical role in cellular invasion and metastasis in numerous human cancers including melanoma (23, 24) .
Activation of RhoA and RhoC GTPases causes subsequent activation of their effector protein, Rho-associated protein kinase (ROCK), which leads to formation of F-actin polymers and resultant depletion of free G-actin monomers (25) . In the cytosol, G-actin monomer binds to the RPEL domain in the N-terminal region of MRTF and sequesters MRTF away from the nucleus (26) . Upon F-actin polymerization during the formation of stress fibers, MRTF translocates to the nucleus, where it cooperates with serum response factor (SRF) to induce transcription of numerous genes involved in cell proliferation and migration (21, 22) . The MRTF-SRF transcriptional axis plays a pro-metastatic role in the context of melanoma and other cancers (27) . Depletion of MRTF via RNA interference (RNAi) in the highly metastatic B16F2 melanoma cell line reduced in vitro cell migration and in vivo lung metastasis (26) . Additionally, pharmacologic inhibition of the Rho/MRTF-pathway by the small-molecule CCG-203971 significantly reduced in vitro cellular migration and invasion (20, 28) , as well as in vivo lung metastasis in the RhoC-expressing NRAS mutant melanoma cell line SK-Mel-147 (20) . In addition to its anti-migratory and anti-metastatic properties, CCG-203971 induced G1-cell cycle arrest in melanoma cells. The recent observation that melanoma cells arrested in the G1 phase have higher sensitivity to MEK inhibitors (29) , suggests a potential benefit of combination treatment with MEK inhibitors and Rho/MRTF pathway inhibitors.
Through structure-activity relationship optimization of CCG-203971, we recently reported the analog CCG-222740 with increased potency of MRTF-pathway inhibition in primary human dermal fibroblasts (30) . Additionally, CCG-222740 demonstrated a greater inhibitory effect on MRTF/SRF target genes (ACTA2 and CTGF) and lesser cytotoxicity than CCG-203971 in a preclinical model of fibrosis (31) . Building on our previous work showing that CCG-203971 inhibited melanoma metastasis, here, we evaluated the pharmacological potential of CCG-222740, a more potent CCG-203971 analog, in combination with a MEK inhibitor (trametinib) in NRAS-mutant melanoma cells. In a panel of NRAS mutant melanoma cell lines, we observed a correlation between the degree of activation of the Rho/MRTF pathway and intrinsic resistance of cells to trametinib-mediated apoptosis. CCG-222740 potentiates trametinib action in the subset of NRAS mutant melanoma cells which had a high level of activation of the Rho/MRTF pathway. In these cells, the combination of trametinib and CCG-222740 cooperatively induced apoptosis and reduced colony formation potential.
MATERIALS AND METHODS

Inhibitors
CCG-222740, previously reported by Hutchings et al. (30) , was a kind gift of Scott Larsen at the Vahltechich Medicinal Chemistry Core (Ann Arbor, MI). CCG-222740 was dissolved in DMSO in 10 mM aliquots and stored at -20 °C. Trametinib (cat# S2673), Vinblastine (cat# S1248), Y-27632 (cat# S1049) were purchased from Selleck Chemicals (Houston, TX), reconstituted in DMSO, and 10 mM aliquots were stored at -20 °C.
Cell Culture and Viability Assay
Human cutaneous melanoma cell lines WM-3451 and WM-3623 were purchased from The 
Clonogenicity Assay
Two hundred cells in DMEM containing 10% FBS were seeded in 6-well dishes and simultaneously treated with vehicle or 6 µM CCG-222740 with or without 0.1 nM or 1 nM Trametinib or with Trametinib alone. Following five days of colony formation, fresh media and compound were added, and colonies were allowed to grow for an additional five days. Colonies were fixed and stained in 3.7% formaldehyde/0.5% crystal violet for 10 minutes at room temperature. Colony counts were quantified using ImageJ software with a cutoff for colony size (pixel^2) fixed at 50-infinity and circularity defined as 0.2-1.0.
Immunofluorescence and F-actin staining
Cells (5x10 4 ) were seeded into Falcon 8 Chamber Slides in 500 µL of DMEM containing 10%
FBS and allowed to adhere overnight. Cells were fixed with 3.7% formaldehyde for 10 minutes at room temperature. Chambers were washed 3 times with 1X PBS for 5 minutes each. Cells were permeabilized with 0.25% Triton X-100 in PBS for 10 minutes followed by 3 imaged on an EVOS FL Cell Imaging System (Life Technologies) at 40X magnification. All scoring of stress fibers and nuclear localization of transcription factors was done by an observer who was blinded to the identity of the sample.
Real-time quantitative PCR (qRT-PCR)
Cells (2x10 5 ) were seeded into 6-well plates and left to adhere overnight then harvested the following day for CYR61 mRNA analysis. Briefly, RNA was isolated using the RNeasy kit 
Western Blot Analysis
Cells (8x10 5 ) were seeded into 60-mm dishes. For both pERK1/2 and pMLC (Phospho-Myosin Following incubation, 100 µL of FACs buffer was added to each well and samples were transferred to 0.5 mL Eppendorf tubes in a 5% CO 2 atmosphere. Fluorescence was detected using a C6 BD Accuri flow cytometer (BD Accuri, San Jose, CA). Fluorescence was quantified using CFLow software (BD Accuri). Events (20,000) were detected in triplicate for all treatment groups and three independent experiments were conducted, and results were averaged. Sequencing was performed at a depth of >30M reads/sample. Quality control was performed on the FastQ files using FastQC v0.11.5, and reads were trimmed using Trimmomatic v0.33.
RNA-Seq sample preparation and data processing
Reads were mapped using HISAT2 v2.1.0 and analyzed using HTSeq v0.6.1. Differential gene expression was calculated using edgeR. Raw RNA-Seq reads and processed HTSeq read counts are available on GEO under GSE134320.
RESULTS
MRTF pathway activation correlates with trametinib resistance
Trametinib is reported to induce apoptosis at varying levels and is overall less potent in NRAS mutant melanoma cells compared to BRAF mutant melanoma cells (5) . We therefore first demonstrated significantly greater trametinib resistance as well as significant variability among NRAS mutant cells compared to SK-Mel-19 ( Fig. 1B) . Melanoma cells harboring NRAS Q61 mutations have previously been shown to have hyperactivation of the MAPK pathway (33) .
Therefore, we quantified pERK1/2 via western blot under basal conditions for each cell line (Fig.   1C ). We found that the levels of pERK1/2 varied substantially across the cell line panel with decreasing amounts of pERK1/2 associated with increased trametinib resistance ( Fig. 1D ).
Our recent findings indicated a role of the Rho/MRTF pathway in migration, invasion and metastasis of aggressive human cutaneous melanoma (20, 34) , as well as in the acquired resistance of BRAF mutant melanoma cells to BRAF inhibitors (34) . Therefore, we hypothesized that the Rho/MRTF pathway might play a role in the intrinsic resistance of some of the NRAS mutant melanoma cells to trametinib-induced inhibition of cell viability. Upon activation of the Rho/MRTF pathway, myosin light chain (MLC) gets phosphorylated and G-actin polymerizes into F-actin stress fibers (35) . Depletion of G-actin during stress fiber formation results in MRTF translocation into the nucleus where it regulates gene transcription, including an increase in cysteine-rich angiogenic inducer 61 (CYR61) (36) . We observed elevated levels of phosphorylated MLC (pMLC) in NRAS mutant cell lines compared to SK-Mel-19, with statistically significantly higher levels of pMLC in SK-Mel-2 cells (Supp. Fig.1 ). We then stained the cells for actin and scored the images for stress fiber positive cells as described in Methods.
Similar to pERK1/2, we detected increased stress fiber formation in NRAS mutant cell lines compared to the BRAF mutant cell line SK-Mel-19. Among NRAS mutant cell lines, SK-Mel-147 cells showed the strongest stress fiber positivity ( Fig. 2A-B ). When we compared the percentage of stress fiber positive cells to trametinib resistance (AUC), we detected a strong positive correlation (r 2 =0.96, p=0.003) (Fig. 2C ). This correlation was still strong when just comparing among NRAS mutant cell lines (r 2 =0.95, p=0.024) Similarly, a significant correlation between the levels of CYR61 mRNA levels and resistance to trametinib (AUC) was also observed for all cells (r 2 =0.92, p=0.012) and for just NRAS mutant cells (r 2 =0.74, p=0.0003) ( Figure 2D ). Since CYR61 gene expression could be regulated upon activation of either the Rho/MRTF pathway via nuclear MRTF-A/B or the Hippo pathway via nuclear YAP, respectively (37), we next studied localization of these transcription factors. Either MRTF-A or MRTF-B were strongly nuclear in 3 of the 4 NRAS mutant cell lines, but not in WM-3451 or SK-Mel-19 cells ( Fig. 2E -F, Supp. Fig. 2A ). Interestingly, WM-3623 only had MRTF-B in the nucleus but not MRTF-A (see Discussion). Finally, we detected a high percentage of cells with nuclear YAP in our cell panel, including the BRAF mutant SK-Mel-19 cells, with no significant differences across the cell lines ( Fig. 2G and Supp. Fig. 2B ). Taken together, these results indicate that Rho/MRTF pathway is activated in NRAS mutant melanoma cell lines having intrinsic resistance to trametinib-induced inhibition of cell proliferation.
MRTF pathway inhibitor, CCG-222740, synergizes with trametinib to reduce viability of
NRAS mutant melanoma cells
Considering a potential role of Rho/MRTF pathway activation in the intrinsic resistance of NRAS mutant cell lines to trametinib treatment, we next sought to determine if the Rho/MRTF-pathway inhibitor CCG-222740 could potentiate the effects of trametinib on viability in our NRAS mutant cell line panel (Fig. 3A) . Using cross-concentration response experiments, we observed that SK-Mel-147 cells demonstrated a significant leftward shift in log IC 50 , with a nearly 2 log-shift at the highest concentration of CCG-222740 utilized (Fig. 3A-B ). WM-3623 cells and SK-Mel-2 cells also displayed potentiation of trametinib effects when trametinib was combined with CCG-222740 (see ∆ log IC 50 plots, Fig. 3A-B ). WM-3451 cells, which had minimal evidence for Rho/MRTF activation, did not display potentiation of trametinib when CCG-222740 was used in combination ( Fig. 3A-B ). To determine if the observed leftward shifts in log IC 50 of trametinib in combination with CCG-222740 represents synergistic effects, we calculated the Loewe Excess in order to derive a synergy score (38) . Synergy (Loewe Excess 1.67-3.03) was observed for the three NRAS mutant cell lines with the greatest intrinsic trametinib resistance, as well as the greatest detected Rho/MRTF-pathway activity. On the other hand, WM-3451 cells did not display evidence of synergy (Fig. 3C ). These results demonstrate that trametinib and CCG-222740 cooperatively reduced the viability of the subset of NRAS mutant melanoma cells lines which have increased Rho/MRTF-pathway activity and high intrinsic trametinib resistance.
CCG-222740 disrupts nuclear localization of MRTF-A and MRTF-B but not YAP
As previously reported (20) for a structurally similar compound, CCG-203971, CCG-222740 effectively reduced MRTF-A nuclear localization in a concentration dependent manner in SK-Mel-147 cells (Fig. 4A-B ). It also reduced the percentage of nuclear MRTF-B ( Fig. 4C-D) , however, there was no significant difference in the nuclear localization of YAP following CCG-222740 treatment (Fig. 4E-F) . We also observed decreased mRNA levels of MRTF target genes CYR61, ANKRD1, CRIM1 and THBS1 upon 24-hour treatment of SK-Mel-147 cells with CCG-222740 in the RNA-Seq analysis ( Supplementary Table S1 ), which was confirmed by qRT-PCR analysis (40-80% decrease, Supplementary Figure S3 ). These results are in accordance with inhibition of Rho/MRTF pathway.
Potentiation of trametinib by CCG-222740 is specific to Rho/MRTF-pathway mechanisms
To determine whether potentiation of trametinib by CCG-222740 is specific to Rho/MRTFpathway inhibition or merely a result of combination with a cytotoxic agent, we first tested trametinib in combination with vinblastine which is a microtubule assembly disrupting chemotherapeutic agent (39) . Vinblastine alone, when used at 1-10 nM, efficiently decreased SK-Mel-147 cell viability, yet when used in combination with trametinib, there was no significant shift in the log IC 50 of trametinib (Fig. 5A) . Also, the synergy score was low, 1.42, for the combination of vinblastine and trametinib (Fig. 5B ). As another agent to perturb Rho/MRTF signaling, we tested the effects of the ROCK inhibitor Y-27632 in combination with trametinib (40) . ROCK signaling is upstream of MRTF activation and is a key component of the Rho/MRTF-pathway. When Y-27632 was used in combination with trametinib in SK-Mel-147 cells, there was a significant shift in log IC 50 , nearly one log difference compared to trametinib alone (Fig. 5C ). The synergy score was also high at 2.11 based on Loewe Excess analysis (Fig.   5D ). These results show that inhibition of the Rho/MRTF-pathway by two distinct agents is synergistic in combination with trametinib, while the effects of the non-targeted agent vinblastine and trametinib are additive.
Combination treatment with trametinib and CCG-222740 induces apoptosis and inhibits clonogenicity in SK-Mel-147 cells.
To evaluate the functional effects of the combination treatment, we measured Caspase3/7 activity as a measure of apoptosis induction. CCG-222740 alone (10 µM) did not affect basal apoptosis as indicated by no change in caspase3/7 activity compared to control (Fig. 6A ). Low nanomolar trametinib increased caspase3/7 activity compared to untreated cells, although the effect was not statistically significant (Fig. 6A ). However, when trametinib was used in combination with CCG-222740, a significant increase in caspase3/7 activity was observed in SK-Mel-147 cells (Fig. 6A) . These data provide evidence that SK-Mel-147 cells, which are highly resistant to trametinib-induced cell death, demonstrate cooperative induction of apoptosis when the Rho/MRTF-pathway inhibitor CCG-222740 is used in combination.
Finally, we performed a colony formation assay to assess clonogenicity of SK-Mel-147 cells in the presence of trametinib and CCG-222740. Treatment with CCG-222740 alone (6 µM) or trametinib alone (1 nM) had no significant effect on the number of colonies formed by SK-Mel-147 cells (Fig. 6B ). However, when cells were treated with 1 nM trametinib and 6 µM CCG-222740 in combination, colony formation was nearly eliminated (Fig. 6B-C) . When we evaluated mean colony area, we detected significant decreases across single agent and combination treatments except for 0.1 nM trametinib alone (Fig. 6D ). The greatest decrease in mean colony area was detected when cells were treated with 1 nM trametinib in combination with 6 µM CCG-222740 ( Fig 6D) . Thus, combination treatment with trametinib and CCG-222470 markedly inhibited clonogenicity of SK-Mel-147 cells.
DISCUSSION:
Given the current lack of approved targeted therapies for NRAS mutant melanoma patients, MEK inhibitors offer a potential treatment option. However, intrinsic and acquired resistance to these inhibitors is a major hurdle. In a recent study, Najem et al. observed that MEK inhibition using pimasertib had only a limited effect on apoptosis in NRAS Q61 mutant melanoma cell lines (14) . MEK inhibitor concentrations is a significant benefit, because severe dose-limiting toxicity is a concern with MEK inhibitors.
We Trametinib resistance correlates with % stress fiber positivity. Utilizing the values depicted in Figure 1B and Figure 2B , a strong positive correlation was observed (r 2 = 0.96, p=0.003, Pearson correlation coefficients, GraphPad Prism). D. CYR61 mRNA levels correlates with Trametinib resistance. Utilizing the values depicted in Figure 2D Sensitivity to trametinib in combination with Vinblastine. Combination treatments were studied in the same manner as described in Figure 3A . The reported values are expressed as the fraction of luminescence over vehicle control for three independent experiments. B. Loewe Excess was utilized as a metric of synergistic effects of the combination treatments in Figure 5A as described in Figure 3C .
Expressed values represent the mean of three independent experiments. C. Sensitivity to trametinib in combination with the ROCK inhibitor Y-27632. Combination treatment was determined in the same manner as described above Figure 3A . D. Loewe Excess was determined for the combination treatments in Figure 5C as described in Figure 3C . Expressed values represent the mean of three independent experiments. 
